Search Results

You are looking at 161 - 170 of 515 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Update on Immunotherapy for Melanoma

Antoni Ribas

. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma . J Clin Oncol 2006 ; 24 : 1188 – 1194 . 17. Spitler LE Grossbard ML Ernstoff MS . Adjuvant therapy of stage III and IV malignant

Full access

New Agents for Colorectal Cancer

Mary F. Mulcahy and Al B. Benson III

G . Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma: German Cancer Aid 17-1A Study Group . Lancet 1994 ; 343 : 1177 – 1183 . 37 Riethmuller G Holz E Schlimok G . Monoclonal

Full access

Colon Cancer

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett

Weeks J . Controversies regarding laparoscopic colectomy for malignant diseases . Curr Opin Gen Surg 1994 : 208 – 213 . 65 Sun W Haller DG . Adjuvant therapy of colon cancer . Semin Oncol 2005 ; 32 : 95 – 102 . 66 Baddi L

Full access

Practice-Changing Interventions in the Systemic Management of Breast Cancer

Presented by: William J. Gradishar

Breast cancer mortality is approximately half of what it was in 1980 due to aggressive screening, combination adjuvant therapies, and the emergence of effective targeted agents for the metastatic setting. “We anticipate that as data emerge from

Full access

Treatment De-Intensification for Patients With HPV-Positive Head and Neck Cancers

Presented by: Maura L. Gillison

(ClinicalTrials.gov identifier: NCT03952585 ). “Those that exceed the landmark PFS and MDADI scores could move forward in a randomized phase III trial,” she said. Can Adjuvant Therapy Be Altered After Primary Surgical Resection? ECOG 3311 was the first

Full access

Targeted Therapy for Metastatic Non–Small Cell Lung Cancer

Presented by: Gregory J. Riely

chemotherapy); and, for nonsquamous histology alone, atezolizumab (proven not beneficial in the squamous subtype when combined with chemotherapy). In addition, data show that ICIs can be used as neoadjuvant or adjuvant therapy for certain patients with

Full access

New NCCN Guidelines for Vulvar Cancer

Benjamin E. Greer and Wui-Jin Koh

extension and N2 as gross disease, Dr. Koh noted. He stated that selecting patients for adjuvant therapy is challenging. Rather than look at the total number of nodes, he suggested using a ratio of the number of positive nodes per side divided by the number

Full access

Evidence-Based Guidelines: Optimizing Imaging in Cancer Care

Pamela J. DiPiro

to satisfy insistent patients. At all stages of cancer care, including at presentation, during neoadjuvant or adjuvant therapy, and in the treatment of advanced disease, evidence-based guidelines are needed to help direct physicians and their patients

Full access

NCCN Guidelines® Insights: Breast Cancer, Version 4.2021

Featured Updates to the NCCN Guidelines

William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice Lyons, Jennifer Matro, Ingrid A. Mayer, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar

Systemic Therapy In patients with early-stage breast cancer, systemic adjuvant therapy is administered to reduce risk of breast cancer recurrence. The decision is often based on individual risk of relapse and predicted sensitivity to treatment (eg

Full access

Adjuvant Chemotherapy for Lung Cancer: Cisplatin Doublets Only?

Daniel Morgensztern and Ramaswamy Govindan

; 4 : 35 – 44 . 22. Keller SM Adak S Wagner H . A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group . N Engl J Med 2000